BioCentury
ARTICLE | Regulation

Who's in charge here?

May 1, 1995 7:00 AM UTC

WASHINGTON - Genzyme Tissue Repair (GENZL) on Friday announced that it voluntarily halted its Carticel cartilage cell service pending resolution of a dispute over regulatory jurisdiction over the knee damage therapy.

The service, developed in Sweden, involves culturing a patient's cartilage cells for use in treating knee damage...